ArticleFrontiers in molecular biosciences2025
STAT3 as a critical target of Sijunzi Decoction in the treatment of gastric cancer: evidence from integrated network pharmacology and experimental validation.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is an importent cause of global cancer mortality, underscoring the need for therapeutic strategies. Traditional Chinese medicine (TCM), particularly Sijunzi Decoction (SJZD), has demonstrated clinical promise as an adjuvant therapy in oncology by improving survival and reducing chemotherapy toxicity. However, the mechanistic basis of SJZD's anti-tumor activity, especially concerning its potential immunomodulatory effects within a competent tumor microenvironment, remains poorly elucidated due to the complexity of its components and limitations of previous preclinical models. Methods: The subcutaneous tumor models were established in inbred 615 mice with MFC cells, and RNA-sequencing (RNA-Seq) was performed on tumor tissues to characterize treatment-associated differentially expressed genes across three groups (model, early Sijunzi Decoction, and synchronization Sijunzi Decoction). Network pharmacology analysis predicted the bioactive compounds and putative targets of Sijunzi Decoction, and constructed a compound-target-disease network to explore potential GC-related pathways. The expression profile of STAT3 in gastric cancer tissues from three groups of mice model was examined through Western blotting assays and immunohistochemistry to determine its role in Gastric cancer and its regulatory relationship. Results: SJZD could prevent tumor growth. Additionally, the earlier Chinese medicine intervention, the more definiter tumor inhibition. The RNA-Seq revealed an immunomodulatory gene signature, as evidenced by the 13 common DEGs significant enrichment in the JAK-STAT pathway. Network pharmacology identified 156 overlapping targets between SJZD and GC, among which STAT3 was recognized as a critical hub gene. Forthermore, Western blot and IHC analysis confirmed that SJZD had downregulated STAT3 protein expression in tumor tissues. Conclusion: SJZD had a definitely inhibitive effect against GC in mice by regulation the STAT3 expression in JAK/STAT signaling pathway, providing a mechanistic rationale for the potential clinical translation of SJZD in GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.